NEW YORK (GenomeWeb) – Molecular diagnostics firm Admera Health announced today that it has signed three deals that will expand the availability of its pharmacogenomics tests in Asia.

Under the first deal, Admera will gain access to the existing physician network of Angsana Molecular & Diagnostics Laboratory, a molecular diagnostic assay developer with offices in Singapore, Hong Kong, and Malaysia. Under the other two deals, South Korea-based Biois and Taiwan-based AllBio Pharma will distribute Admera's full product portfolio.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.